MX2012003201A - Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina. - Google Patents
Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.Info
- Publication number
- MX2012003201A MX2012003201A MX2012003201A MX2012003201A MX2012003201A MX 2012003201 A MX2012003201 A MX 2012003201A MX 2012003201 A MX2012003201 A MX 2012003201A MX 2012003201 A MX2012003201 A MX 2012003201A MX 2012003201 A MX2012003201 A MX 2012003201A
- Authority
- MX
- Mexico
- Prior art keywords
- ceftaroline
- compositions
- methods
- bacterial infections
- treat bacterial
- Prior art date
Links
- 229940036735 ceftaroline Drugs 0.000 title abstract 5
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- RGFBRLNVZCCMSV-BIRGHMBHSA-N ceftaroline Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(N)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 RGFBRLNVZCCMSV-BIRGHMBHSA-N 0.000 title 1
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- ITHCSGCUQDMYAI-ZMIZWQJLSA-N 2-carboxy-D-arabinitol 1,5-bisphosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@](O)(COP(O)(O)=O)C(O)=O ITHCSGCUQDMYAI-ZMIZWQJLSA-N 0.000 abstract 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 abstract 1
- 102100021486 Protein S100-G Human genes 0.000 abstract 1
- 101710122252 Protein S100-G Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
Abstract
La presente invención se refiere a composiciones que comprenden ceftarolina o un profármaco de esta (p. ej., ceftarolina fosamilo) y métodos para tratar infecciones bacterianas, tales como infecciones complicadas de la piel y sus estructuras (cSSSI), y la neumonía bacteriana adquirida en la comunidad (CABP), administrando ceftarolina o un profármaco de esta (p. ej ., ceftarolina fosamilo).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24412009P | 2009-09-21 | 2009-09-21 | |
| US29490110P | 2010-01-14 | 2010-01-14 | |
| PCT/US2010/049659 WO2011035305A1 (en) | 2009-09-21 | 2010-09-21 | Compositions and methods for treating bacterial infections using ceftaroline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012003201A true MX2012003201A (es) | 2012-05-08 |
Family
ID=43757152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012003201A MX2012003201A (es) | 2009-09-21 | 2010-09-21 | Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina. |
| MX2012003411A MX2012003411A (es) | 2009-09-21 | 2010-09-21 | Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012003411A MX2012003411A (es) | 2009-09-21 | 2010-09-21 | Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20110071114A1 (es) |
| EP (1) | EP2480236A4 (es) |
| KR (1) | KR20120083344A (es) |
| CN (1) | CN102781451A (es) |
| AU (1) | AU2010295269B2 (es) |
| BR (1) | BR112012006250B1 (es) |
| CA (1) | CA2774772A1 (es) |
| CL (1) | CL2012000694A1 (es) |
| CO (1) | CO6531417A2 (es) |
| CR (1) | CR20120137A (es) |
| CU (1) | CU20120048A7 (es) |
| DO (1) | DOP2012000077A (es) |
| EA (1) | EA029149B1 (es) |
| EC (1) | ECSP12011739A (es) |
| GT (1) | GT201200082A (es) |
| HN (1) | HN2012000585A (es) |
| IL (1) | IL218349A0 (es) |
| MX (2) | MX2012003201A (es) |
| NI (1) | NI201200045A (es) |
| PE (2) | PE20171176A1 (es) |
| PH (1) | PH12012500528A1 (es) |
| SG (1) | SG178936A1 (es) |
| WO (1) | WO2011035305A1 (es) |
| ZA (1) | ZA201202924B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2951171A1 (fr) * | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| WO2012172368A1 (en) | 2011-06-17 | 2012-12-20 | Astrazeneca Ab | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
| CN107621512B (zh) * | 2017-11-02 | 2020-07-31 | 扬子江药业集团有限公司 | 一种柱前衍生化法测定头孢洛林酯侧链酰氯纯度的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW473479B (en) * | 1997-12-19 | 2002-01-21 | Takeda Chemical Industries Ltd | Phosphonocephem derivatives, their production and use |
| CN1189471C (zh) * | 2000-08-10 | 2005-02-16 | 武田药品工业株式会社 | 膦酰基头孢烯化合物 |
| WO2002093162A2 (en) * | 2001-05-17 | 2002-11-21 | Mcgill University | Individualization of therapy with antibiotic agents |
| CA2477088A1 (en) * | 2002-02-22 | 2003-10-02 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| CN101868240A (zh) * | 2007-09-21 | 2010-10-20 | 阿斯利康(瑞典)有限公司 | 适合肠胃外给药的包含头孢烯衍生物的可溶剂型 |
-
2010
- 2010-09-21 AU AU2010295269A patent/AU2010295269B2/en active Active
- 2010-09-21 MX MX2012003201A patent/MX2012003201A/es not_active Application Discontinuation
- 2010-09-21 WO PCT/US2010/049659 patent/WO2011035305A1/en not_active Ceased
- 2010-09-21 BR BR112012006250-6A patent/BR112012006250B1/pt active IP Right Grant
- 2010-09-21 PE PE2016002751A patent/PE20171176A1/es unknown
- 2010-09-21 PH PH1/2012/500528A patent/PH12012500528A1/en unknown
- 2010-09-21 KR KR1020127007154A patent/KR20120083344A/ko not_active Ceased
- 2010-09-21 EA EA201200501A patent/EA029149B1/ru unknown
- 2010-09-21 US US12/887,140 patent/US20110071114A1/en not_active Abandoned
- 2010-09-21 PE PE2012000354A patent/PE20121819A1/es not_active Application Discontinuation
- 2010-09-21 MX MX2012003411A patent/MX2012003411A/es unknown
- 2010-09-21 CN CN2010800537030A patent/CN102781451A/zh active Pending
- 2010-09-21 CA CA2774772A patent/CA2774772A1/en not_active Abandoned
- 2010-09-21 EP EP10818022.5A patent/EP2480236A4/en not_active Withdrawn
- 2010-09-21 SG SG2012014510A patent/SG178936A1/en unknown
-
2012
- 2012-02-27 IL IL218349A patent/IL218349A0/en unknown
- 2012-03-20 CL CL2012000694A patent/CL2012000694A1/es unknown
- 2012-03-20 HN HN2012000585A patent/HN2012000585A/es unknown
- 2012-03-21 CR CR20120137A patent/CR20120137A/es unknown
- 2012-03-21 GT GT201200082A patent/GT201200082A/es unknown
- 2012-03-21 CO CO12048072A patent/CO6531417A2/es not_active Application Discontinuation
- 2012-03-21 CU CU2012000048A patent/CU20120048A7/es unknown
- 2012-03-21 EC ECSP12011739 patent/ECSP12011739A/es unknown
- 2012-03-21 NI NI201200045A patent/NI201200045A/es unknown
- 2012-03-21 DO DO2012000077A patent/DOP2012000077A/es unknown
- 2012-04-20 ZA ZA2012/02924A patent/ZA201202924B/en unknown
-
2015
- 2015-05-27 US US14/722,495 patent/US9629861B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NI201200045A (es) | 2012-11-02 |
| PE20171176A1 (es) | 2017-08-22 |
| US20110071114A1 (en) | 2011-03-24 |
| WO2011035305A1 (en) | 2011-03-24 |
| ECSP12011739A (es) | 2012-05-30 |
| AU2010295269A1 (en) | 2012-04-12 |
| GT201200082A (es) | 2014-12-22 |
| AU2010295269B2 (en) | 2014-06-05 |
| CO6531417A2 (es) | 2012-09-28 |
| KR20120083344A (ko) | 2012-07-25 |
| CA2774772A1 (en) | 2011-03-24 |
| IL218349A0 (en) | 2012-04-30 |
| BR112012006250A2 (pt) | 2016-05-31 |
| PH12012500528A1 (en) | 2019-06-14 |
| CL2012000694A1 (es) | 2012-08-31 |
| HN2012000585A (es) | 2015-06-15 |
| CR20120137A (es) | 2012-05-28 |
| US20150258126A1 (en) | 2015-09-17 |
| PE20121819A1 (es) | 2013-02-01 |
| EA029149B1 (ru) | 2018-02-28 |
| ZA201202924B (en) | 2012-12-27 |
| CU20120048A7 (es) | 2012-10-15 |
| DOP2012000077A (es) | 2012-05-31 |
| US9629861B2 (en) | 2017-04-25 |
| EA201200501A1 (ru) | 2012-10-30 |
| EP2480236A1 (en) | 2012-08-01 |
| CN102781451A (zh) | 2012-11-14 |
| EP2480236A4 (en) | 2013-04-17 |
| SG178936A1 (en) | 2012-04-27 |
| MX2012003411A (es) | 2012-04-30 |
| BR112012006250B1 (pt) | 2021-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
| UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
| CR20120264A (es) | Compuestos | |
| PA8819201A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| CR20110407A (es) | Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido | |
| NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
| CR20110509A (es) | Composicion farmaceutica | |
| UY35391A (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c | |
| BR112016012862A2 (pt) | formulações para vacinas para neoplasia | |
| CR20110558A (es) | ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS Y MÉTODOS DE USO | |
| BR112012020693A8 (pt) | Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende | |
| GT201200016A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
| CR20120510A (es) | Derivados de piperidin-4-il azetidina como inhibidores de jak1 | |
| UY32427A (es) | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
| GT201400097A (es) | Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr) | |
| BR112012009329A2 (pt) | derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia) | |
| HN2011003011A (es) | Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas | |
| EA201170832A1 (ru) | Пуриновые соединения | |
| BR112012019302A2 (pt) | imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met | |
| BR112013000776A2 (pt) | método e formulação para tratamento de deficiência de ácido siálico | |
| CL2017003066A1 (es) | Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal | |
| CR20130602A (es) | Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa | |
| BR112012014760A2 (pt) | "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso" | |
| BR112012019920A2 (pt) | derivados de piridazina úteis como agonístas de canabinoide-2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |